Text Size

Effects of Omega 3 in Hemodialysis Patients

This study has been completed.
Sponsor:
Information provided by:
Laboratoire Régional de Nutrition Humaine
ClinicalTrials.gov Identifier:
NCT00431899
First received: February 3, 2007
Last updated: NA
Last verified: February 2007
History: No changes posted
  Purpose

The aim of the study was to determine the effects of a 3-week fish oil oral supplementation on the metabolic fate and thermogenic effect of an oral glucose load in hemodialysis patients.


Condition Intervention
Hemodialysis
End Stage Renal Disease
 Behavioral: fish oil supplementation

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: Effets of Fish Oil on Metabolic Fate of an Oral Glucose Load in Patients With End Stage Renal Disease Undergoing Hemodialysis

Resource links provided by NLM:

Drug Information available for: Fish oil
U.S. FDA Resources

Further study details as provided by Laboratoire Régional de Nutrition Humaine:

Primary Outcome Measures:
  • plasma glucose utilization
  • glucose-induced thermogenesis

Estimated Enrollment: 8
Study Start Date: May 2003
Estimated Study Completion Date: November 2003
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • hemodialysis at least 6 months duration end stage renal disease

Exclusion Criteria:

  • - Age < 18 y ou > 75 y
  • Hemodialysis < 6 months
  • Diabetes, obesity
  • allergy to fish
  • Asthma
  • glucocorticoïds, propranolol,, Immunosuppressive drugs, Insulin, Somatostatin
  • erythropoïetin < 3 months
  • Cancer
  • Hemoglobin < 11 g/l
  • disease < 1 month
  • pregnancy
  • respiratory insufficiency
  • intensive sport practice
  • refusal
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00431899

Locations
France
Laboratoire Régional de Nutrition Humaine
Brest, 29, France, F-29200
Sponsors and Collaborators
Laboratoire Régional de Nutrition Humaine
Investigators
Principal Investigator: Jacques Delarue, MD,PhD CHU Cavale Blanche F-29200 Brest
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00431899     History of Changes
Other Study ID Numbers: HDW3
Study First Received: February 3, 2007
Last Updated: February 3, 2007
Health Authority: France: Ministry of Health

Keywords provided by Laboratoire Régional de Nutrition Humaine:
nutrition
omega 3 fatty acids
insulin resistance

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency

ClinicalTrials.gov processed this record on June 17, 2013